-
Je něco špatně v tomto záznamu ?
Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness
R. Holaj, J. Rosa, T. Zelinka, B. Štrauch, O. Petrák, T. Indra, Z. Šomlóová, D. Michalský, K. Novák, D. Wichterle, J. Widimský,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
Grantová podpora
NT14155
MZ0
CEP - Centrální evidence projektů
- MeSH
- adenom komplikace chirurgie MeSH
- adrenalektomie * MeSH
- aldosteron krev MeSH
- antagonisté mineralokortikoidních receptorů terapeutické užití MeSH
- dospělí MeSH
- hyperaldosteronismus farmakoterapie etiologie chirurgie MeSH
- intimomediální šíře tepenné stěny * MeSH
- krevní tlak MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory nadledvin komplikace chirurgie MeSH
- následné studie MeSH
- prospektivní studie MeSH
- senioři MeSH
- spironolakton terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
BACKGROUND: Aldosterone has been shown to substantially contribute to the accumulation of different types of collagen fibres and growth factors in the arterial wall, thus increasing wall thickness. A previous study showed reduction of increased common carotid intima-media thickness (IMT) in patients with primary aldosteronism 1 year after adrenalectomy. Our study in patients with primary aldosteronism was aimed at comparing the long-term effect of adrenalectomy vs. spironolactone therapy on common carotid IMT regression. METHOD: Forty-two patients with confirmed primary aldosteronism (21 with aldosterone-producing adenoma treated by unilateral laparoscopic adrenalectomy, 21 treated with spironolactone) were investigated by carotid ultrasound at baseline and 1 and 6 years after the specific treatment. RESULTS: There was a decrease in common carotid IMT from 0.956 ± 0.140 to 0.900 ± 0.127 mm (-5.9%; P < 0.05) at 1 year and to 0.866 ± 0.130 mm (-9.4%; P < 0.01) at 6 years after adrenalectomy; in the spironolactone group, common carotid IMT decreased from 0.917 ± 0.151 to 0.900 ± 0.165 mm (-1.8%; NS) at 1 year and to 0.854 ± 0.176 mm (-6.8%; P < 0.01) at 6 years of treatment. The magnitude of improvement at 1 year was significantly higher (by 70%; P < 0.05) in the adrenalectomy group; however, the difference (by 27%) became nonsignificant at 6 years. Comparing the adrenalectomy and spironolactone groups, there was no significant difference in blood pressure decrease after treatment. CONCLUSION: In the long term, spironolactone therapy in patients with primary aldosteronism had significant effect on regression of IMT, which was comparable to surgical treatment in patients with unilateral forms of primary aldosteronism.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16021019
- 003
- CZ-PrNML
- 005
- 20190926083326.0
- 007
- ta
- 008
- 160722s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/HJH.0000000000000464 $2 doi
- 024 7_
- $a 10.1097/HJH.0000000000000464 $2 doi
- 035 __
- $a (PubMed)25490707
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Holaj, Robert, $u 3rd Department of Medicine b1st Department of Surgery cDepartment of Urology, Centre for Hypertension General University Hospital and 1st Faculty of Medicine, Charles University in Prague ; Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1965- $7 xx0074140
- 245 10
- $a Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness / $c R. Holaj, J. Rosa, T. Zelinka, B. Štrauch, O. Petrák, T. Indra, Z. Šomlóová, D. Michalský, K. Novák, D. Wichterle, J. Widimský,
- 520 9_
- $a BACKGROUND: Aldosterone has been shown to substantially contribute to the accumulation of different types of collagen fibres and growth factors in the arterial wall, thus increasing wall thickness. A previous study showed reduction of increased common carotid intima-media thickness (IMT) in patients with primary aldosteronism 1 year after adrenalectomy. Our study in patients with primary aldosteronism was aimed at comparing the long-term effect of adrenalectomy vs. spironolactone therapy on common carotid IMT regression. METHOD: Forty-two patients with confirmed primary aldosteronism (21 with aldosterone-producing adenoma treated by unilateral laparoscopic adrenalectomy, 21 treated with spironolactone) were investigated by carotid ultrasound at baseline and 1 and 6 years after the specific treatment. RESULTS: There was a decrease in common carotid IMT from 0.956 ± 0.140 to 0.900 ± 0.127 mm (-5.9%; P < 0.05) at 1 year and to 0.866 ± 0.130 mm (-9.4%; P < 0.01) at 6 years after adrenalectomy; in the spironolactone group, common carotid IMT decreased from 0.917 ± 0.151 to 0.900 ± 0.165 mm (-1.8%; NS) at 1 year and to 0.854 ± 0.176 mm (-6.8%; P < 0.01) at 6 years of treatment. The magnitude of improvement at 1 year was significantly higher (by 70%; P < 0.05) in the adrenalectomy group; however, the difference (by 27%) became nonsignificant at 6 years. Comparing the adrenalectomy and spironolactone groups, there was no significant difference in blood pressure decrease after treatment. CONCLUSION: In the long term, spironolactone therapy in patients with primary aldosteronism had significant effect on regression of IMT, which was comparable to surgical treatment in patients with unilateral forms of primary aldosteronism.
- 650 _2
- $a adenom $x komplikace $x chirurgie $7 D000236
- 650 _2
- $a nádory nadledvin $x komplikace $x chirurgie $7 D000310
- 650 12
- $a adrenalektomie $7 D000315
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a aldosteron $x krev $7 D000450
- 650 _2
- $a krevní tlak $7 D001794
- 650 12
- $a intimomediální šíře tepenné stěny $7 D059168
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperaldosteronismus $x farmakoterapie $x etiologie $x chirurgie $7 D006929
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a antagonisté mineralokortikoidních receptorů $x terapeutické užití $7 D000451
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a spironolakton $x terapeutické užití $7 D013148
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rosa, Ján $7 xx0229097
- 700 1_
- $a Zelinka, Tomáš $7 xx0074465
- 700 1_
- $a Štrauch, Branislav $7 xx0035015
- 700 1_
- $a Petrák, Ondřej $7 xx0104500
- 700 1_
- $a Indra, Tomáš $7 xx0236186
- 700 1_
- $a Šomlóová, Z. $d 1983- $7 av2016929974
- 700 1_
- $a Michalský, David $7 xx0091243
- 700 1_
- $a Novák, Květoslav, $d 1966- $7 xx0063922
- 700 1_
- $a Wichterle, Dan $7 xx0101417
- 700 1_
- $a Widimský, Jiří, $d 1956- $7 jn99240001422
- 773 0_
- $w MED00002723 $t Journal of hypertension $x 1473-5598 $g Roč. 33, č. 4 (2015), s. 874-882; discussion 882
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25490707 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20190926083726 $b ABA008
- 999 __
- $a ok $b bmc $g 1155689 $s 945547
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 33 $c 4 $d 874-882; discussion 882 $i 1473-5598 $m Journal of hypertension $n J Hypertens $x MED00002723
- GRA __
- $a NT14155 $p MZ0
- LZP __
- $a Pubmed-20160722
